XML 19 R2.htm IDEA: XBRL DOCUMENT
v3.23.1

Pay vs Performance Disclosure | 4 Months Ended | 8 Months Ended | 12 Months Ended | 36 Months Ended
--- | --- | --- | --- | ---
Dec. 31, 2020 | Sep. 13, 2020 | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2022 $ / shares
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Pay vs Performance [Table Text Block] |  |  | Pay Versus Performance Our compensation programs are designed to align compensation with business objectives and our financial performance, and to attract, retain, motivate, focus, and reward executives in order to enhance our long-term growth and profitability, foster stockholder value creation, and align executives’ interests with those of our stockholders. As required by Item 402(v) of Regulation S-K, we are providing the following information about the relationships between compensation actually paid to our named executive officers and company performance. In this section, we refer to compensation actually paid (“CAP”) and other terms used in the applicable SEC rules. For information concerning our compensation philosophy, refer to “Compensation Discussion and Analysis” above. Pay Versus Performance Table
Year | ​ | ​ | Reported Summary Compensation Table (“SCT”) Total for PEO 1 | ​ | ​ | Compensation Actually Paid to PEO 1(2) | ​ | ​ | Reported Summary Compensation Table Total for PEO 2 | ​ | ​ | Compensation Actually Paid to PEO 2(2) | ​ | ​ | Average Reported Summary Compensation Table Total for Non-PEO NEOs(3) | ​ | ​ | Average Compensation Actually Paid to Non-PEO NEOs(2)(3) | ​ | ​ | Value of Initial Fixed $100 Investment(1) | ​ | ​ | Net Income (in millions) | ​ | ​ | Company Selected Measure: Revenue (in millions)(5) | ​
​ | Company Total Shareholder Return | ​ | ​ | Peer Group Shareholder Return(4) | ​
2022 | ​ | ​ | ​ | $ | 6,616,251 | ​ | ​ | ​ | ​ | $ | (13,137,692) | ​ | ​ | ​ | ​ | ​ | N/A | ​ | ​ | ​ | ​ | ​ | N/A | ​ | ​ | ​ | ​ | $ | 4,472,247 | ​ | ​ | ​ | ​ | $ | (842,693) | ​ | ​ | ​ | ​ | $ | 159 | ​ | ​ | ​ | ​ | $ | 114 | ​ | ​ | ​ | ​ | $ | (314.2) | ​ | ​ | ​ | ​ | $ | 128.3 | ​ | ​
2021 | ​ | ​ | ​ | $ | 2,866,931 | ​ | ​ | ​ | ​ | $ | (6,449,458) | ​ | ​ | ​ | ​ | ​ | N/A | ​ | ​ | ​ | ​ | ​ | N/A | ​ | ​ | ​ | ​ | $ | 11,099,491 | ​ | ​ | ​ | ​ | $ | 6,128,515 | ​ | ​ | ​ | ​ | $ | 398 | ​ | ​ | ​ | ​ | $ | 126 | ​ | ​ | ​ | ​ | $ | (181.2) | ​ | ​ | ​ | ​ | $ | 130.5 | ​ | ​
2020 | ​ | ​ | ​ | $ | 12,478,770 | ​ | ​ | ​ | ​ | $ | 51,604,237 | ​ | ​ | ​ | ​ | $ | 1,717,050 | ​ | ​ | ​ | ​ | $ | 8,398,519 | ​ | ​ | ​ | ​ | $ | 1,855,694 | ​ | ​ | ​ | ​ | $ | 4,749,166 | ​ | ​ | ​ | ​ | $ | 505 | ​ | ​ | ​ | ​ | $ | 126 | ​ | ​ | ​ | ​ | $ | 29.4 | ​ | ​ | ​ | ​ | $ | 78.9 | ​ | ​
​ (1) Total shareholder return is calculated by assuming that a $100 investment was made on at the close of trading on December 31, 2019 and reinvesting all dividends until the last day of each reported fiscal year. ​ (2) The SEC rules require that certain adjustments be made to the Summary Compensation Table totals to determine CAP, as reported in the Pay versus Performance table above. The following table details the applicable adjustments that were made to determine CAP. ​
Year | ​ | ​ | Executives | ​ | ​ | SCT Total | ​ | ​ | Deduct SCT Stock & Option Awards | ​ | ​ | Add Year-End Value of Unvested Awards Granted in Year(a) | ​ | ​ | Add Change in Value of Unvested Awards Granted in Prior Years(a) | ​ | ​ | Add Fair Value of Vested Awards Granted in Year(a) | ​ | ​ | Add Change in Value of Vested Awards Granted in Prior Years(a) | ​ | ​ | Deduct Fair Value of Forfeited Awards in Year(a) | ​
2022 2022 | ​ | ​ | PEO 1 | ​ | ​ | ​ | $ | 6,616,251 | ​ | ​ | ​ | ​ | $ | (5,517,997) | ​ | ​ | ​ | ​ | $ | 3,572,661 | ​ | ​ | ​ | ​ | $ | (11,593,565) | ​ | ​ | ​ | ​ | $ | 485,101 | ​ | ​ | ​ | ​ | $ | (6,700,144) | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​
​ | Non-PEO NEOs* | ​ | ​ | ​ | $ | 4,472,247 | ​ | ​ | ​ | ​ | $ | (3,944,226) | ​ | ​ | ​ | ​ | $ | 2,962,458 | ​ | ​ | ​ | ​ | $ | (2,161,553) | ​ | ​ | ​ | ​ | $ | 141,415 | ​ | ​ | ​ | ​ | $ | (1,075,233) | ​ | ​ | ​ | ​ | $ | (1,237,802) | ​ | ​
2021 2021 | ​ | ​ | PEO 1 | ​ | ​ | ​ | $ | 2,866,931 | ​ | ​ | ​ | ​ | $ | (1,448,052) | ​ | ​ | ​ | ​ | $ | 574,247 | ​ | ​ | ​ | ​ | $ | (8,880,638) | ​ | ​ | ​ | ​ | $ | 94,868 | ​ | ​ | ​ | ​ | $ | 343,184 | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​
​ | Non-PEO NEOs* | ​ | ​ | ​ | $ | 11,099,491 | ​ | ​ | ​ | ​ | $ | (10,246,763) | ​ | ​ | ​ | ​ | $ | 5,818,159 | ​ | ​ | ​ | ​ | $ | (603,005) | ​ | ​ | ​ | ​ | $ | 25,851 | ​ | ​ | ​ | ​ | $ | 34,783 | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​
2020 2020 2020 | ​ | ​ | PEO 1 | ​ | ​ | ​ | $ | 12,478,770 | ​ | ​ | ​ | ​ | $ | (11,835,900) | ​ | ​ | ​ | ​ | $ | 50,961,367 | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​
​ | PEO 2 | ​ | ​ | ​ | $ | 1,717,050 | ​ | ​ | ​ | ​ | $ | (551,250) | ​ | ​ | ​ | ​ | $ | 3,891,000 | ​ | ​ | ​ | ​ | $ | 592,015 | ​ | ​ | ​ | ​ | $ | 1,945,500 | ​ | ​ | ​ | ​ | $ | 1,061,203 | ​ | ​ | ​ | ​ | $ | (257,000) | ​ | ​
​ | Non-PEO NEOs* | ​ | ​ | ​ | $ | 1,855,694 | ​ | ​ | ​ | ​ | $ | (1,535,473) | ​ | ​ | ​ | ​ | $ | 4,481,588 | ​ | ​ | ​ | ​ | $ | 138,827 | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​ | ​ | ​ | $ | (8,737) | ​ | ​ | ​ | ​ | $ | (182,732) | ​ | ​
​ * Presented on an averaged basis ​ (a) For purposes of the adjustments to determine “compensation actually paid”, we computed the fair value of equity awards as of each measurement date using valuation assumptions and methodologies (including expected term, volatility, dividend yield and risk-free interest rates) that are consistent with those used to estimate fair value at grant under U.S. GAAP. The valuation assumptions used to calculate option fair values differed materially from those disclosed at the time of grant in the following ways: ​ • Risk-free rates range from 0.13% to 4.42% for the pay-versus-performance valuations versus a range of 0.28% to 3.66% for grant-date valuations. The risk-free rates differed due to macroeconomic changes between the grant date and valuation dates. ​ • The expected option term estimates range from 2.17 years to 8.71 years for the pay versus performance valuations versus 4.6 years and 6.10 for the grant date valuations. The expected term changed from the grant date to incorporate the passage of time in the awards’ life and by the degree to which the option was in or out of the money. ​ • The volatilities range from 60.45% to 92.45% for the pay versus performance valuations versus 67.00% – 75.45% for grant date valuations. The volatility differed due to macroeconomic changes in the market for our common stock between the grant date and valuation dates. ​ • The stock price on the valuation date ranged from $2.80 to $50.32 for the pay versus performance valuations versus $2.45 to $46.37 for grant date valuations. ​ All other valuation assumptions are not materially different from the grant-date assumptions and there were no changes in calculation methodology. For additional details on the valuation assumptions used at grant, see Note 10. “Stockholders’ Equity” to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. (3) The NEOs for each applicable year are: ​ • 2022: PEO: Christian O. Henry. Non-PEO NEOs: Susan Kim, Mark Van Oene, Jeff Eidel, and Peter Fromen. Mr. Fromen resigned from his role as Chief Commercial Officer effective May 20, 2022. Mr. Eidel was appointed as Chief Commercial Officer effective August 16, 2022. ​ • 2021: PEO: Christian O. Henry. Non-PEO NEOs: Susan Kim, Mark Van Oene, Peter Fromen, and Denis Zaccarin. Dr. Zaccarin ceased to serve as an executive officer after January 8, 2021. Mr. Van Oene was appointed as Chief Operating Officer, and Mr. Fromen was appointed Chief Commercial Officer, effective January 8, 2021. ​ • 2020: PEO 1: Christian O. Henry. PEO 2: Michael Hunkapiller. Dr. Hunkapiller stepped down from his role as Chief Executive Officer and President effective September 14, 2020. Non-PEO NEOs: Susan Kim, Susan Barnes, and Denis Zaccarin. Ms. Barnes retired from her role as Executive Vice President and Chief Financial Officer effective August 7, 2020. Mr. Henry was appointed as President and Chief Executive Officer effective September 14, 2020, and Ms. Kim was appointed as Chief Financial Officer effective September 28, 2020. ​ (4) The peer group used for relative TSR is the Nasdaq Biotechnology Index, which is the same peer group we use for the stock performance graph included in this proxy statement pursuant to Item 201(e) of Regulation S-K. ​ (5) The company-selected measure is revenue, as described above in “Compensation Discussion and Analysis.” Revenue means all GAAP-based revenue as reflected in our audited financial statements. |  |  |
Company Selected Measure Name |  |  | Revenue |  |  |
Named Executive Officers, Footnote [Text Block] |  |  | (3) The NEOs for each applicable year are: ​ • 2022: PEO: Christian O. Henry. Non-PEO NEOs: Susan Kim, Mark Van Oene, Jeff Eidel, and Peter Fromen. Mr. Fromen resigned from his role as Chief Commercial Officer effective May 20, 2022. Mr. Eidel was appointed as Chief Commercial Officer effective August 16, 2022. ​ • 2021: PEO: Christian O. Henry. Non-PEO NEOs: Susan Kim, Mark Van Oene, Peter Fromen, and Denis Zaccarin. Dr. Zaccarin ceased to serve as an executive officer after January 8, 2021. Mr. Van Oene was appointed as Chief Operating Officer, and Mr. Fromen was appointed Chief Commercial Officer, effective January 8, 2021. ​ • 2020: PEO 1: Christian O. Henry. PEO 2: Michael Hunkapiller. Dr. Hunkapiller stepped down from his role as Chief Executive Officer and President effective September 14, 2020. Non-PEO NEOs: Susan Kim, Susan Barnes, and Denis Zaccarin. Ms. Barnes retired from her role as Executive Vice President and Chief Financial Officer effective August 7, 2020. Mr. Henry was appointed as President and Chief Executive Officer effective September 14, 2020, and Ms. Kim was appointed as Chief Financial Officer effective September 28, 2020. |  |  |
Peer Group Issuers, Footnote [Text Block] |  |  | (4) The peer group used for relative TSR is the Nasdaq Biotechnology Index, which is the same peer group we use for the stock performance graph included in this proxy statement pursuant to Item 201(e) of Regulation S-K. |  |  |
Adjustment To PEO Compensation, Footnote [Text Block] |  |  | (2) The SEC rules require that certain adjustments be made to the Summary Compensation Table totals to determine CAP, as reported in the Pay versus Performance table above. The following table details the applicable adjustments that were made to determine CAP. ​
Year | ​ | ​ | Executives | ​ | ​ | SCT Total | ​ | ​ | Deduct SCT Stock & Option Awards | ​ | ​ | Add Year-End Value of Unvested Awards Granted in Year(a) | ​ | ​ | Add Change in Value of Unvested Awards Granted in Prior Years(a) | ​ | ​ | Add Fair Value of Vested Awards Granted in Year(a) | ​ | ​ | Add Change in Value of Vested Awards Granted in Prior Years(a) | ​ | ​ | Deduct Fair Value of Forfeited Awards in Year(a) | ​
2022 2022 | ​ | ​ | PEO 1 | ​ | ​ | ​ | $ | 6,616,251 | ​ | ​ | ​ | ​ | $ | (5,517,997) | ​ | ​ | ​ | ​ | $ | 3,572,661 | ​ | ​ | ​ | ​ | $ | (11,593,565) | ​ | ​ | ​ | ​ | $ | 485,101 | ​ | ​ | ​ | ​ | $ | (6,700,144) | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​
​ | Non-PEO NEOs* | ​ | ​ | ​ | $ | 4,472,247 | ​ | ​ | ​ | ​ | $ | (3,944,226) | ​ | ​ | ​ | ​ | $ | 2,962,458 | ​ | ​ | ​ | ​ | $ | (2,161,553) | ​ | ​ | ​ | ​ | $ | 141,415 | ​ | ​ | ​ | ​ | $ | (1,075,233) | ​ | ​ | ​ | ​ | $ | (1,237,802) | ​ | ​
2021 2021 | ​ | ​ | PEO 1 | ​ | ​ | ​ | $ | 2,866,931 | ​ | ​ | ​ | ​ | $ | (1,448,052) | ​ | ​ | ​ | ​ | $ | 574,247 | ​ | ​ | ​ | ​ | $ | (8,880,638) | ​ | ​ | ​ | ​ | $ | 94,868 | ​ | ​ | ​ | ​ | $ | 343,184 | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​
​ | Non-PEO NEOs* | ​ | ​ | ​ | $ | 11,099,491 | ​ | ​ | ​ | ​ | $ | (10,246,763) | ​ | ​ | ​ | ​ | $ | 5,818,159 | ​ | ​ | ​ | ​ | $ | (603,005) | ​ | ​ | ​ | ​ | $ | 25,851 | ​ | ​ | ​ | ​ | $ | 34,783 | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​
2020 2020 2020 | ​ | ​ | PEO 1 | ​ | ​ | ​ | $ | 12,478,770 | ​ | ​ | ​ | ​ | $ | (11,835,900) | ​ | ​ | ​ | ​ | $ | 50,961,367 | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​
​ | PEO 2 | ​ | ​ | ​ | $ | 1,717,050 | ​ | ​ | ​ | ​ | $ | (551,250) | ​ | ​ | ​ | ​ | $ | 3,891,000 | ​ | ​ | ​ | ​ | $ | 592,015 | ​ | ​ | ​ | ​ | $ | 1,945,500 | ​ | ​ | ​ | ​ | $ | 1,061,203 | ​ | ​ | ​ | ​ | $ | (257,000) | ​ | ​
​ | Non-PEO NEOs* | ​ | ​ | ​ | $ | 1,855,694 | ​ | ​ | ​ | ​ | $ | (1,535,473) | ​ | ​ | ​ | ​ | $ | 4,481,588 | ​ | ​ | ​ | ​ | $ | 138,827 | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​ | ​ | ​ | $ | (8,737) | ​ | ​ | ​ | ​ | $ | (182,732) | ​ | ​
​ * Presented on an averaged basis ​ (a) For purposes of the adjustments to determine “compensation actually paid”, we computed the fair value of equity awards as of each measurement date using valuation assumptions and methodologies (including expected term, volatility, dividend yield and risk-free interest rates) that are consistent with those used to estimate fair value at grant under U.S. GAAP. The valuation assumptions used to calculate option fair values differed materially from those disclosed at the time of grant in the following ways: ​ • Risk-free rates range from 0.13% to 4.42% for the pay-versus-performance valuations versus a range of 0.28% to 3.66% for grant-date valuations. The risk-free rates differed due to macroeconomic changes between the grant date and valuation dates. ​ • The expected option term estimates range from 2.17 years to 8.71 years for the pay versus performance valuations versus 4.6 years and 6.10 for the grant date valuations. The expected term changed from the grant date to incorporate the passage of time in the awards’ life and by the degree to which the option was in or out of the money. ​ • The volatilities range from 60.45% to 92.45% for the pay versus performance valuations versus 67.00% – 75.45% for grant date valuations. The volatility differed due to macroeconomic changes in the market for our common stock between the grant date and valuation dates. ​ • The stock price on the valuation date ranged from $2.80 to $50.32 for the pay versus performance valuations versus $2.45 to $46.37 for grant date valuations. ​ All other valuation assumptions are not materially different from the grant-date assumptions and there were no changes in calculation methodology. For additional details on the valuation assumptions used at grant, see Note 10. “Stockholders’ Equity” to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. |  |  |
Non-PEO NEO Average Total Compensation Amount |  |  | $ 4,472,247 | $ 11,099,491 | $ 1,855,694 |
Non-PEO NEO Average Compensation Actually Paid Amount |  |  | $ (842,693) | 6,128,515 | 4,749,166 |
Adjustment to Non-PEO NEO Compensation Footnote [Text Block] |  |  | (2) The SEC rules require that certain adjustments be made to the Summary Compensation Table totals to determine CAP, as reported in the Pay versus Performance table above. The following table details the applicable adjustments that were made to determine CAP. ​
Year | ​ | ​ | Executives | ​ | ​ | SCT Total | ​ | ​ | Deduct SCT Stock & Option Awards | ​ | ​ | Add Year-End Value of Unvested Awards Granted in Year(a) | ​ | ​ | Add Change in Value of Unvested Awards Granted in Prior Years(a) | ​ | ​ | Add Fair Value of Vested Awards Granted in Year(a) | ​ | ​ | Add Change in Value of Vested Awards Granted in Prior Years(a) | ​ | ​ | Deduct Fair Value of Forfeited Awards in Year(a) | ​
2022 2022 | ​ | ​ | PEO 1 | ​ | ​ | ​ | $ | 6,616,251 | ​ | ​ | ​ | ​ | $ | (5,517,997) | ​ | ​ | ​ | ​ | $ | 3,572,661 | ​ | ​ | ​ | ​ | $ | (11,593,565) | ​ | ​ | ​ | ​ | $ | 485,101 | ​ | ​ | ​ | ​ | $ | (6,700,144) | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​
​ | Non-PEO NEOs* | ​ | ​ | ​ | $ | 4,472,247 | ​ | ​ | ​ | ​ | $ | (3,944,226) | ​ | ​ | ​ | ​ | $ | 2,962,458 | ​ | ​ | ​ | ​ | $ | (2,161,553) | ​ | ​ | ​ | ​ | $ | 141,415 | ​ | ​ | ​ | ​ | $ | (1,075,233) | ​ | ​ | ​ | ​ | $ | (1,237,802) | ​ | ​
2021 2021 | ​ | ​ | PEO 1 | ​ | ​ | ​ | $ | 2,866,931 | ​ | ​ | ​ | ​ | $ | (1,448,052) | ​ | ​ | ​ | ​ | $ | 574,247 | ​ | ​ | ​ | ​ | $ | (8,880,638) | ​ | ​ | ​ | ​ | $ | 94,868 | ​ | ​ | ​ | ​ | $ | 343,184 | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​
​ | Non-PEO NEOs* | ​ | ​ | ​ | $ | 11,099,491 | ​ | ​ | ​ | ​ | $ | (10,246,763) | ​ | ​ | ​ | ​ | $ | 5,818,159 | ​ | ​ | ​ | ​ | $ | (603,005) | ​ | ​ | ​ | ​ | $ | 25,851 | ​ | ​ | ​ | ​ | $ | 34,783 | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​
2020 2020 2020 | ​ | ​ | PEO 1 | ​ | ​ | ​ | $ | 12,478,770 | ​ | ​ | ​ | ​ | $ | (11,835,900) | ​ | ​ | ​ | ​ | $ | 50,961,367 | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​
​ | PEO 2 | ​ | ​ | ​ | $ | 1,717,050 | ​ | ​ | ​ | ​ | $ | (551,250) | ​ | ​ | ​ | ​ | $ | 3,891,000 | ​ | ​ | ​ | ​ | $ | 592,015 | ​ | ​ | ​ | ​ | $ | 1,945,500 | ​ | ​ | ​ | ​ | $ | 1,061,203 | ​ | ​ | ​ | ​ | $ | (257,000) | ​ | ​
​ | Non-PEO NEOs* | ​ | ​ | ​ | $ | 1,855,694 | ​ | ​ | ​ | ​ | $ | (1,535,473) | ​ | ​ | ​ | ​ | $ | 4,481,588 | ​ | ​ | ​ | ​ | $ | 138,827 | ​ | ​ | ​ | ​ | $ | 0 | ​ | ​ | ​ | ​ | $ | (8,737) | ​ | ​ | ​ | ​ | $ | (182,732) | ​ | ​
​ * Presented on an averaged basis ​ (a) For purposes of the adjustments to determine “compensation actually paid”, we computed the fair value of equity awards as of each measurement date using valuation assumptions and methodologies (including expected term, volatility, dividend yield and risk-free interest rates) that are consistent with those used to estimate fair value at grant under U.S. GAAP. The valuation assumptions used to calculate option fair values differed materially from those disclosed at the time of grant in the following ways: ​ • Risk-free rates range from 0.13% to 4.42% for the pay-versus-performance valuations versus a range of 0.28% to 3.66% for grant-date valuations. The risk-free rates differed due to macroeconomic changes between the grant date and valuation dates. ​ • The expected option term estimates range from 2.17 years to 8.71 years for the pay versus performance valuations versus 4.6 years and 6.10 for the grant date valuations. The expected term changed from the grant date to incorporate the passage of time in the awards’ life and by the degree to which the option was in or out of the money. ​ • The volatilities range from 60.45% to 92.45% for the pay versus performance valuations versus 67.00% – 75.45% for grant date valuations. The volatility differed due to macroeconomic changes in the market for our common stock between the grant date and valuation dates. ​ • The stock price on the valuation date ranged from $2.80 to $50.32 for the pay versus performance valuations versus $2.45 to $46.37 for grant date valuations. ​ All other valuation assumptions are not materially different from the grant-date assumptions and there were no changes in calculation methodology. For additional details on the valuation assumptions used at grant, see Note 10. “Stockholders’ Equity” to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. |  |  |
Tabular List [Table Text Block] |  |  | Most Important Financial Performance Measures The financial performance measures listed below represent the most important financial performance measures that were used to determine the compensation actually paid to our NEOs in 2022. No other financial performance measures were used to determine compensation actually paid to our named executive officers for 2022.
​ | Most Important Financial Performance Measures | ​
​ | Revenue | ​
​ | Non-GAAP Gross Margin | ​
​ | Adjusted EBITDA | ​
Total Shareholder Return Amount |  |  | $ 159 | 398 | 505 |
Peer Group Total Shareholder Return Amount |  |  | 114 | 126 | 126 |
Net Income (Loss) |  |  | $ (314,200,000) | $ (181,200,000) | $ 29,400,000 |
Company Selected Measure Amount |  |  | 128,300,000 | 130,500,000 | 78,900,000 |
PEO Name | Christian O. Henry | Michael Hunkapiller | Christian O. Henry | Christian O. Henry |  |
Measure [Axis]: 1 |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Measure Name |  |  | Revenue |  |  |
Non-GAAP Measure Description [Text Block] |  |  | (5) The company-selected measure is revenue, as described above in “Compensation Discussion and Analysis.” Revenue means all GAAP-based revenue as reflected in our audited financial statements. |  |  |
Measure [Axis]: 2 |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Measure Name |  |  | Non-GAAP Gross Margin |  |  |
Measure [Axis]: 3 |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Measure Name |  |  | Adjusted EBITDA |  |  |
Pay Vs Performance Valuations Date [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum |  |  |  |  |  | 0.13%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum |  |  |  |  |  | 4.42%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term, Minimum |  |  |  |  |  | 2 years 2 months 1 day
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term, Maximum |  |  |  |  |  | 8 years 8 months 15 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum |  |  |  |  |  | 60.45%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum |  |  |  |  |  | 92.45%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Stock Price Minimum | $ / shares |  |  |  |  |  | $ 2.8
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Stock Price Maximum | $ / shares |  |  |  |  |  | $ 50.32
Grant Date Valuations [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum |  |  |  |  |  | 0.28%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum |  |  |  |  |  | 3.66%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term, Minimum |  |  |  |  |  | 4 years 7 months 6 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term, Maximum |  |  |  |  |  | 6 years 1 month 6 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum |  |  |  |  |  | 67.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum |  |  |  |  |  | 75.45%
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Stock Price Minimum | $ / shares |  |  |  |  |  | $ 2.45
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Stock Price Maximum | $ / shares |  |  |  |  |  | $ 46.37
Christian O Henry [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
PEO Total Compensation Amount |  |  | $ 6,616,251 | $ 2,866,931 | $ 12,478,770 |
PEO Actually Paid Compensation Amount |  |  | (13,137,692) | (6,449,458) | 51,604,237 |
Christian O Henry [Member] | Equity Awards Value In Summary Compensation Table (Grant Date Value) |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount |  |  | (5,517,997) | (1,448,052) | (11,835,900) |
Christian O Henry [Member] | Year-end Fair Value Of Awards Granted In The Current Fiscal Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount |  |  | 3,572,661 | 574,247 | 50,961,367 |
Christian O Henry [Member] | Change In Fair Value Of Outstanding And Unvested Awards Granted In Prior Fiscal Years [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount |  |  | (11,593,565) | (8,880,638) | 0 |
Christian O Henry [Member] | Change In Fair Value As Of Vesting Date Of Current Year Awards Vested During Current Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount |  |  | 485,101 | 94,868 | 0 |
Christian O Henry [Member] | Change In Fair Value As Of Vesting Date Of Prior Year Awards Vested During Current Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount |  |  | (6,700,144) | 343,184 | 0 |
Christian O Henry [Member] | Change in Fair Value Of Forfeited Awards In Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount |  |  | 0 | 0 | 0 |
Michael Hunkapiller [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
PEO Total Compensation Amount |  |  |  |  | 1,717,050 |
PEO Actually Paid Compensation Amount |  |  |  |  | 8,398,519 |
Michael Hunkapiller [Member] | Equity Awards Value In Summary Compensation Table (Grant Date Value) |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount |  |  |  |  | (551,250) |
Michael Hunkapiller [Member] | Year-end Fair Value Of Awards Granted In The Current Fiscal Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount |  |  |  |  | 3,891,000 |
Michael Hunkapiller [Member] | Change In Fair Value Of Outstanding And Unvested Awards Granted In Prior Fiscal Years [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount |  |  |  |  | 592,015 |
Michael Hunkapiller [Member] | Change In Fair Value As Of Vesting Date Of Current Year Awards Vested During Current Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount |  |  |  |  | 1,945,500 |
Michael Hunkapiller [Member] | Change In Fair Value As Of Vesting Date Of Prior Year Awards Vested During Current Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount |  |  |  |  | 1,061,203 |
Michael Hunkapiller [Member] | Change in Fair Value Of Forfeited Awards In Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount |  |  |  |  | (257,000) |
Non-PEO NEO [Member] | Equity Awards Value In Summary Compensation Table (Grant Date Value) |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount |  |  | (3,944,226) | (10,246,763) | (1,535,473) |
Non-PEO NEO [Member] | Year-end Fair Value Of Awards Granted In The Current Fiscal Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount |  |  | 2,962,458 | 5,818,159 | 4,481,588 |
Non-PEO NEO [Member] | Change In Fair Value Of Outstanding And Unvested Awards Granted In Prior Fiscal Years [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount |  |  | (2,161,553) | (603,005) | 138,827 |
Non-PEO NEO [Member] | Change In Fair Value As Of Vesting Date Of Current Year Awards Vested During Current Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount |  |  | 141,415 | 25,851 | 0 |
Non-PEO NEO [Member] | Change In Fair Value As Of Vesting Date Of Prior Year Awards Vested During Current Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount |  |  | (1,075,233) | 34,783 | (8,737) |
Non-PEO NEO [Member] | Change in Fair Value Of Forfeited Awards In Year [Member] |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |
Adjustment to Compensation Amount |  |  | $ (1,237,802) | $ 0 | $ (182,732) |

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_MeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_NonGaapMeasureDescriptionTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupIssuersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupTotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 6 + Details
Name: | ecd_TabularListTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum
Namespace Prefix: | pacb_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum
Namespace Prefix: | pacb_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPriceMaximum
Namespace Prefix: | pacb_
Data Type: | dtr:perShareItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | pacb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPriceMinimum
Namespace Prefix: | pacb_
Data Type: | dtr:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 65 -Paragraph 1 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 50 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 60B -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580 Reference 25: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794 Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794 Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760 Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580 Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum risk-free interest rate assumption that is used in valuing an option on its own shares. + References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The minimum risk-free interest rate assumption that is used in valuing an option on its own shares. + References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ecd_MeasureAxis=1
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=2
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=3
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=pacb_PayVsPerformanceValuationsDateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=pacb_GrantDateValuationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=pacb_ChristianOHenryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=pacb_EquityAwardsValueInCompensationTableForTheApplicableYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=pacb_EquityAwardsAdjustmentsYearEndFairValueOfAwardsGrantedInCurrentYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=pacb_EquityAwardsAdjustmentsChangeInFairValueAsOfYearEndOfOutstandingAndUnvestedAwardsGrantedInPriorYearsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=pacb_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfCurrentAwardsVestedDuringCurrentYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=pacb_EquityAwardsAdjustmentsChangeInFairValueAsOfVestingDateOfPriorYearAwardsVestedDuringCurrentYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=pacb_EquityAwardsAdjustmentsChangeInFairValueOfForfeitedAwardsInYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=pacb_MichaelHunkapillerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |